Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06753331 · ClinicalTrials.gov registry record · Phase 1
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
A Phase 1 study of Parkinson's Disease, sponsored by Sumitomo Pharma America.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06753331 is a Phase 1 study of Parkinson's Disease that is actively recruiting participants, run by Sumitomo Pharma America. The registered enrollment target is 25 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06753331, a Phase 1 study of Parkinson's Disease, is actively recruiting participants, sponsored by Sumitomo Pharma America.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States
Conditions Studied
Interventions
- COMBINATION_PRODUCT DSP-1083 implantation
- PROCEDURE Sham surgery treatment
Study Locations (2)
Kentucky
- University of Kentucky Medical Center - Lexington
New York
- New York Presbyterian Hospital-Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2030-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06753331
The ClinicalTrials.gov registry entry for NCT06753331 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (96% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which DSP-1083 implantation is the first listed.
NCT06753331 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kentucky, New York.
Frequently Asked Questions
What is clinical trial NCT06753331 about?
NCT06753331 is a clinical study titled "A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease". The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States
What is the current status of trial NCT06753331?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-12-18. Estimated completion is 2030-12-15.
What conditions does trial NCT06753331 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT06753331?
The interventions under investigation include: DSP-1083 implantation (COMBINATION_PRODUCT), Sham surgery treatment (PROCEDURE).
Who is sponsoring clinical trial NCT06753331?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06753331 being conducted?
This trial has 2 study locations across Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
-
Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.